key: cord-0874028-aua88s62
authors: Rijkers, Ger; Vervenne, Trees; van der Pol, Pieter
title: More bricks in the wall against SARS-CoV-2 infection: involvement of γ9δ2 T cells
date: 2020-05-28
journal: Cell Mol Immunol
DOI: 10.1038/s41423-020-0473-0
sha: 22d352749ed9fbda4050bc6524aae6470bad0a68
doc_id: 874028
cord_uid: aua88s62

nan

The SARS-CoV-2 virus which emerged in late December 2019 had reached pandemic proportions by March 2020. 1 Host defence mechanisms against this new member of the corona virus family will include innate immunity, humoral, and cellular immune responses, of yet unknown relative importance. Conventional CD8 + αβTCR cytotoxic T cells and natural killer cells are mainly responsible for detection and elimination of virus infected cells, with a special role for the CD94/NK group 2 member A (NKG2A) receptor as reported by Zheng et al. in this journal. 2, 3 We want to report yet another brick in the wall against SARS-CoV-2 infection, made of a subset of γδTCR T cells. 4 Poccia et al. previously described that in peripheral blood of health care workers who survived a SARS-CoV infection during the 2003 outbreak, a selective expansion of the Vγ9Vδ2 T-cell population was found 3 months after the onset of disease. 4 This subset of γδ T cells also has been implicated in influenza infections. 5, 6 We have therefore analyzed the frequency and activation status of Vγ9Vδ2 T cells in hospitalized patients (n = 24) with PCR proven SARS-CoV-2 infection (Supplementary Table 1 ). We find that the percentage of Vγ9Vδ2 T cells at the moment of hospital admission (on average 10 days after onset of clinical symptoms) is significantly lower than that of matched healthy controls ( Fig. 1 ) (healthy controls 1.82 ± 0.41 × 10 4 Vγ9Vδ2 T cells/ ml, COVID-19 patients 0.38 ± 0.40 × 10 4 /ml ; p < 0.05). Six patients died while being hospitalized (four of them in the ICU) and they showed T lymphocytopenia, including decreased numbers of Vγ9Vδ2 T cells (0.06 ± 0.38 × 10 4 /ml; Fig. 1 ). In five patients we could monitor the phenotype of Vγ9Vδ2 T cells during the 2 weeks they were admitted to the hospital. During that period, on average 26% of the Vγ9Vδ2 T-cell population shifts to a phenotype of effector (memory) cells, as compared with 8% within the total T-cell population.

It has been shown that Vγ9Vδ2 T cells have a so-called polycytotoxic profile. 6 Vγ9Vδ2 cells are the dominant γδ T-cell population in adults, but in the elderly this is more variable. 6, 7 Our data could indicate that elderly with reduced numbers of Vγ9Vδ2 T cells constitute the SARS-CoV-2 vulnerable population. Alternatively, the Vγ9Vδ2 T cells in these patients have migrated to the lungs to kill SARS-CoV-2 infected cells. Long term monitoring of these patients should make this clear.

Vγ9Vδ2 T cells do not recognize antigens presented by HLA molecules but use the alternative antigen presenting molecule BTN3A. 8 ICT01, a humanized activating anti-BTN3A antibody, is currently in Phase 1 studies for potential use in anticancer Table 2) and measured by flow cytometry on a BD FACSLyric instrument (BD Biosciences, San Jose, CA, USA). Data analysis was performed with Infinicyt flow cytometry software (Cytognos, Capelle aan de IJssel, The Netherlands). Lymphocytes were gated on basis of CD45 and scatter characteristics. a, b Show the percentage of CD3 + , CD4 − , CD8 bright − T-lymphocytes expressing Vγ9 TCR and/or Vδ2 TCR of a representative COVID-19 patient and a healthy control donor, respectively. The boxed areas represents the Vγ9Vδ2 TCR T lymphocytes. c The numbers of Vγ9Vδ2 TCR T lymphocytes per ml are given for healthy controls and COVID-19 patients that died or survived. Patients who died of COVID-19 had a significant lower number of Vγ9Vδ2 TCR T lymphocytes (*p < 0.05 by two-sided Student T test). N.S. not significant therapy. 9 In the context of the data presented here, this antibody could offer an alternative treatment strategy for COVID-19.

The study was performed in accordance with the guidelines for sharing of patient data of observational scientific research in emergency situations as issued by the Commission on Codes of Conduct of the Foundation Federation of Dutch Medical Scientific Societies (https://www.federa.org/federa-english).

WHO declares COVID-19 a pandemic

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

NKG2A and COVID-19: another brick in the wall

Gammadelta-T cells: an unpolished sword in human anti-infection immunity

Anti-severe acute respiratory syndrome coronavirus immune responses: the role played by V gamma 9V delta 2 T cells

Human γδ T-cell receptor repertoire is shaped by influenza viruses, age and tissue compartmentalisation

The human Vδ2(+) T-cell compartment comprises distinct innate-like Vγ9(+) and adaptive Vγ9(−) subsets

New Insights Into the Regulation of γδ T Cells by BTN3A and Other BTN/BTNL in tumor

γδ T cells bring unconventional cancer-targeting to the clinic-again

The online version of this article (https://doi.org/10.1038/s41423-020-0473-0) contains supplementary material.Competing interests: The authors declare no competing interests.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons. org/licenses/by/4.0/.